Navigation Links
UAlberta medical researchers discover potential new treatment for colitis
Date:10/23/2013

A drug currently on the market to treat leukemia reversed symptoms of colitis in lab tests, according to recently published findings by medical researchers with the University of Alberta.

Faculty of Medicine & Dentistry researcher Shairaz Baksh published his team's discovery in the peer-reviewed journal, PLOS ONE.

His team discovered that a tumour-suppressor gene can also play an important role in the development of colitis. When this gene quits working or is missing, the inflammation process is triggered and the body loses its ability to repair damaged colon tissue. This leads to severe discomfort and poor recovery following bouts of inflammation. Persistent inflammation is prevalent in inflammatory bowel disease (such as Crohn's disease and ulcerative colitis).

Baksh and his team wondered if they could interfere with the inflammation process and encourage the body to repair the damaged tissue, so the disease would be less severe and patients could recover more quickly from any flare-ups. The team used a leukemia drug (imatinib/gleevec) that has been on the market for years to treat normal mice and mice that were missing the tumour-suppressor gene.

"The treatment reversed the symptoms of colitis," says Baksh. "We are on the cusp of a new treatment for this condition that affects 150,000 Canadians. We are pretty excited about the impact of this finding.

"We are trying to inhibit colitis by preventing the inflammation that is causing the damage. More importantly, by controlling or preventing the inflammation, we can reduce the likelihood that patients with ulcerative colitis develop colorectal cancer later in life. About half of these patients develop this type of cancer due to chronic inflammation.

"Our findings also suggest we may have identified novel biomarkers for the appearance and progression of inflammatory bowel disease."

His team is continuing its work in this area and has discovered that other drugs currently on the market have the same effect in reducing the symptoms of colitis in mice. He hopes to publish the new drug study results very soon, and suspects a new treatment for colitis could be a combination of two to three drugs already on the market.

A combination drug therapy would need to undergo further testing in the lab, but could go to clinical trials in about five years since the medications are already approved.

About 0.5 per cent of Canadians have colitis. The incidence is higher in Alberta than in other provinces and studies are currently underway to identify the hot spots in the province. Genetics, diet and environment each play an important role in the development of the disease. Symptoms include weight loss, rectal bleeding and weight loss. Patients with the condition have ulcerated and inflamed colons, which are shorter than average and cause a great deal of discomfort.

Baksh examines the link between inflammation and cancer. About one-third of cancers start due to chronic inflammation, he says. For example, about 40 to 50 per cent of patients with ulcerative colitis (a form of inflammatory bowel disease) later develop colorectal cancer; those with chronic bronchitis are prone to developing lung cancer; and acute pancreatitis often leads to pancreatic cancer. Hence, there is a great need to understand how inflammation is a "pre-condition" for cancer, says Baksh.

Baksh is a researcher in the Department of Pediatrics, the Department of Biochemistry and the Division of Experimental Oncology.

His research was funded by Alberta Innovates Health Solutions, the Hair Massacure and the Canadian Institutes of Health Research.

Tammy MacDonald, who founded the Hair Massacure fundraiser and helped fund this research, spoke of a young family member's diagnosis with leukemia in 2000 - a diagnosis that would have been a death sentence at one time.

"Today, due to ongoing research and clinical trials, the odds of beating many cancers have significantly increased. Still, we have not found a cure. We felt that continuing the journey of research will inevitably lead us there.

"Dr. Baksh is our chosen researcher. We are extremely thankful for his expertise, passion and accountability. Dr. Baksh's discovery and interest in colitis and inflammatory diseases, as it relates to pre-cancers, adds a more thorough approach to seeking proactive treatments that could prevent cancer."


'/>"/>

Contact: Raquel Maurier
rmaurier@ualberta.ca
780-492-5986
University of Alberta Faculty of Medicine & Dentistry
Source:Eurekalert

Related biology news :

1. UAlberta medical researchers discover how immune system kills healthy cells
2. Diets high in salt could deplete calcium in the body: UAlberta research
3. Paper-based device could bring medical testing to remote locales
4. Study finds natural compound can be used for 3-D printing of medical implants
5. Research!America honors leaders in medical and health research advocacy
6. Medbox Partners with Licensed Medical Cannabis Laboratory and Cultivation Center in Canada
7. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
8. New NIH-funded resource focuses on use of genomic variants in medical care
9. NIH announces awards to strengthen the biomedical research workforce
10. MARC travel awards announced for the 2013 Biomedical Engineering Society annual meeting
11. Meeting: Straight Talk: The Future of Medical and Health Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology: